Abstract

CGRP, adrenomedullin (ADM), and adrenomedullin 2 (ADM2) family peptides are important neuropeptides and hormones for the regulation of neurotransmission, vasotone, cardiovascular morphogenesis, vascular integrity, and feto-placental development. These peptides signal through CLR/RAMP1, 2 and 3 receptor complexes. CLR/RAMP1, or CGRP receptor, antagonists have been developed for the treatment of migraine headache and osteoarthritis pain; whereas CLR/RAMP2, or ADM receptor, antagonists are being developed for the treatment of tumor growth/metastasis. Based on the finding that an acylated chimeric ADM/ADM2 analog potently stimulates CLR/RAMP1 and 2 signaling, we hypothesized that the binding domain of this analog could have potent inhibitory activity on CLR/RAMP receptors. Consistent with this hypothesis, we showed that acylated truncated ADM/ADM2 analogs of 27–31 residues exhibit potent antagonistic activity toward CLR/RAMP1 and 2. On the other hand, nonacylated analogs have minimal activity. Further truncation at the junctional region of these chimeric analogs led to the generation of CLR/RAMP1-selective antagonists. A 17-amino-acid analog (Antagonist 2–4) showed 100-fold selectivity for CLR/RAMP1 and was >100-fold more potent than the classic CGRP receptor antagonist CGRP8-37. In addition, we showed (1) a lysine residue in the Antagonist 2–4 is important for enhancing the antagonistic activity, (2) an analog consisted of an ADM sequence motif and a 12-amino-acid binding domain of CGRP exhibits potent CLR/RAMP1-inhibitory activity, and (3) a chimeric analog consisted of a somatostatin analog and an ADM antagonist exhibits dual activities on somatostatin and CLR/RAMP receptors. Because the blockage of CLR/RAMP signaling prevents migraine pain and suppresses tumor growth/metastasis, further studies of these analogs, which presumably have better access to the tumor microenvironment and nerve endings at the trigeminal ganglion and synovial joints as compared to antibody-based therapies, may lead to the development of better anti-CGRP therapy and alternative antiangiogenesis therapy. Likewise, the use of bifunctional somatostatin-ADM antagonist analogs could be a promising strategy for the treatment of high-grade neuroendocrine tumors by targeting an antiangiogenesis agent to the neuroendocrine tumor microenvironment.
Introduction

CLR/RAMP1, 2 and 3 complexes are cognate receptors for four peptides hormones, including α- and β-calcitonin gene-related peptides (α- and β-CGRPs), adrenomedullin (ADM), and adrenomedullin 2 (ADM2, or intermedin [IMD]) [1–5]. The CLR/RAMP receptor complexes contain two transmembrane components, the calcitonin receptor-like receptor (CLR) and one of the three receptor activity-modifying proteins (RAMP1, 2, and 3) [3–7]. Whereas CGRPs mainly act through the CLR/RAMP1 receptor, ADM has high affinity for CLR/RAMP2 and 3 receptors [6, 8]. On the other hand, ADM2 is a weak ligand and exhibits no distinct preference for the three CLR/RAMP receptors. Earlier studies have shown that ADM plays critical roles in the regulation of cardiovascular development, vasotone, endothelial barrier integrity, and tumor angiogenesis [3, 9–29]. Likewise, ADM2 is important for the regulation of vascular lumen enlargement, and exerts vaso- and cardio-protective effects in animals with hypertension, heart failure, ischemia reperfusion injury, obesity, or insulin resistance [30–33]. By contrast, CGRPs are important for the regulation of nociception, hyperalgesia, and allodynia [34–37].

Excessive release of CGRP is associated with the development of migraine headache, osteoarthritis pain, complex regional pain syndrome, and diabetic neuropathy [38, 39]; whereas ADM signaling is associated with tumor growth/metastasis. As such, CLR/RAMP receptor antagonists have been developed for the treatment of pain and tumor growth. Four distinct approaches have been used to block CLR/RAMP signaling: (1) peptide antagonists (e.g., CGRP8-37 and ADM22-52) [40–44], (2) small molecule antagonists (e.g., telcagepant for CLR/RAMP1) [25, 45, 46], (3) anti-CGRP or anti-ADM antibodies (e.g., galcanezumab and fremanezumab) [29, 47–50], and (4) anti-CLR or anti-RAMP antibodies (e.g., erenumab) [29, 48–51]. Although several small molecule CGRP antagonists (e.g., telcagepant) are effective in reducing migraine headache, most of them suffered concerns of liver toxicity [52]. By contrast, anti-CGRP and anti-RAMP1 antibodies have been approved as anti-migraine therapies in 2018 [36, 39, 51–56]. On the other hand, because blockage of ADM signaling suppresses tumor xenograft growth and metastasis in animals [26, 29, 43, 47, 49, 57], ADM antagonists are being developed as anti-tumor/angiogenesis therapy [26, 29, 43, 47, 49, 57, 58].

Although anti-CGRP antibody therapies showed efficacy in patients, they are inadequate for the control of severe migraine in many patients and are ineffective for reducing osteoarthritis pain [59–61]. Therefore, there is still a substantial unmet medical need of therapeutics that can better control CLR/RAMP-mediated pain response and tumor growth/angiogenesis. Because peptide antagonists have a volume of distribution ~3 times that of a typical antibody, they have better access to target receptors at the nerve endings and the tumor microenvironment. Therefore, peptide antagonists may represent alternative candidates for the development of anti-CGRP and anti-ADM therapies.

Recently, we have discovered that an acylated chimeric ADM/ADM2 analog exhibits potent agonistic activity for CLR/RAMP1 and 2. Based on this finding, we hypothesized that the binding domain of this chimeric analog could be a useful building block to develop novel CLR/RAMP receptor antagonists. In addition, because N-terminal acylation, benzylation, or dibenzylation of CGRP8-37 improves the affinity toward CGRP receptor [62], we further hypothesized that acylation modification may improve the antagonistic activity of chimeric analogs. Accordingly, we analyzed a series of acylated truncated ADM/ADM2 analogs. Consistent with our hypothesis, several of these chimeric analogs exhibit potent pan-specific or CLR/RAMP1-selective antagonistic activities. In addition, analysis of a chimeric analog consisted of a somatostatin analog and an ADM antagonist motif showed the analog exhibits potent somatostatin receptor-activation andCLR/RAMP receptor-inhibitory activities. As such, this
new class of antagonistic analogs could be useful for the development of alternative anti-CGRP and novel targeted antiangiogenesis therapeutics.

Materials and methods

Materials
ADM, CGRP, CGRP8-37, ADM22–52 and chimeric analogs were synthesized using solid-phase peptide synthesis methodologies and obtained from Genscript Inc., Lifetein, or Karebay Inc. The synthesized product was purified by analytical RP-HPLC to >95% purity. The identity of the purified products was confirmed by MS spectrometry.

Design of CLR/RAMP1 and 2 signaling assays
The bioactivity of synthetic analogs was studied using cells that stably express CLR/RAMP1 (1321N1 cells) or CLR/RAMP2 (CHO-K1 cells) receptors using CLR/RAMP1 cAMP and CLR/RAMP2 arrestin assays from DiscoveRx (Fremont, Ca). In receptor-activation assays, the dose-dependent stimulatory response was studied in duplicate, at 10 different concentrations. Half maximal effective concentration (EC₅₀) and half maximal inhibitory concentration (IC₅₀) were performed using 10-point dose response curves with a starting concentration of 1.0 or 10 μM and serially diluted 3-fold, in DMSO. Human β-CGRP was used as a positive control in the CLR/RAMP1 assay, and ADM was used as a positive control in the CLR/RAMP2 assay.

Assay of CLR/RAMP1 signaling
For the analysis of signaling in CLR/RAMP1-expressing cells, cAMP Hunter cell lines were expanded from freezer stocks [63], and cells were seeded in white walled, 384-well microplates and incubated at 37°C for the appropriate time. The activity was determined using the DiscoveRx HitHunter cAMP XS+ assay. Media was aspirated from cells and replaced with 15 μl 2:1 HBSS/10mM Hepes:cAMP XS+ Ab reagent. Intermediate dilution of sample stocks was performed to generate 4X sample in assay buffer, and 5 μl of 4X sample was added to cells and incubated at 37°C or room temperature for the appropriate time. Vehicle concentration was 1%.

For the determination of antagonistic activity, cells were pre-incubated with sample followed by agonist challenge at the EC₈₀ concentration. Known antagonists, including BIBN4096BS, CGRP8-37, and ADM22-52 were used as controls. Media was aspirated from cells and replaced with 10 μl 1:1 HBSS/Hepes:cAMP XS+ Ab reagent, and 5 μl of 4X compound was added to the cells and incubated at 37°C or room temperature for 30 minutes. Then, 5 μl of 4X EC₈₀ agonist was added to cells and incubated at 37°C or room temperature for the appropriate time.

After compound incubation, assay signal was generated through incubation with 20 μl cAMP XS+ ED/CL lysis cocktail for 1 hr followed by incubation with 20 μl cAMP XS+ EA reagent for 3 hr at room temperature. Microplates were read with a PerkinElmer instrument for chemiluminescent signal detection. The compound activity was analyzed using a CBIS data analysis suite (ChemInnovation, CA). For agonist mode assays, percentage activity was calculated using the following formula: % Activity = 100% x (mean RLU of test sample—mean RLU of vehicle control)/(mean MAX control ligand—mean RLU of vehicle control). For antagonistic activity assays, percentage inhibition was calculated using the following formula: % Inhibition = 100% x (1 - (mean RLU of test sample—mean RLU of vehicle control)/(mean RLU of EC₈₀ control—mean RLU of vehicle control)).
Assay of CLR/RAMP2 receptor signaling

The CLR/RAMP2 signaling was assayed using the CLR/RAMP2 PathHunter β-Arrestin assay [64]. In this assay, the GPCR was fused in frame with a small enzyme donor fragment ProLink (PK) and co-expressed in cells stably expressing a fusion protein of β-arrestin and an N-terminal deletion mutant of β-galactosidase (i.e., enzyme acceptor or EA). Activation of the CLR/RAMP2 stimulates binding of β-arrestin to the PK-tagged receptor and leads to an increase in enzyme activity that can be measured using chemiluminescent PathHunter Detection Reagents. PathHunter cell lines were seeded in white walled, 384-well microplates and incubated at 37°C prior to testing. For agonist determination, intermediate dilution of sample stocks was performed to generate 5X sample in assay buffer, and 5 μl of 5X sample was added to cells and incubated at 37°C for 90 minutes. Vehicle concentration was 1%. For antagonistic activity determination, cells were pre-incubated with antagonist followed by agonist challenge at the EC_{50} concentration. Assay signal was generated through a single addition of 12.5 or 15 μl (50% v/v) of PathHunter Detection reagent cocktail, followed by 1 hr incubation at room temperature.

Assay of somatostatin receptor 2 (SSTR2) signaling

The effect of somatostatin-related peptides on somatostatin receptor 2 (SSTR2) signaling was assayed using the cAMP Hunter CHO-K1 SSTR2 Assay (DiscoveRx Inc.). Cells overexpressing SSTR2 were cultured and assayed using the agonistic mode as described for the study of CLR/RAMP1 receptor signaling. The functional status of the receptor was monitored by measuring the cellular cAMP levels using a gain-of-signal competitive immunoassay based on a β-galactosidase enzyme fragment complementation method.

Results

Design of CLR/RAMP receptor agonists and antagonists

In an effort to characterize the interaction of ADM2 with CLR/RAMP receptors, we found that an acylated chimeric ADM/ADM2 analog (Agonist 1, Fig 1) potently stimulates CLR/RAMP2 signaling (Table 1). The receptor-activation activity of this analog was distinctly different from those of wild-type CGRP, ADM, and ADM2, which are not acylated (Table 1; Fig 2). The EC_{50} of wild-type ADM (i.e., ADM1-52 or ADM14-52) for CLR/RAMP2 is ~9–12 nM; whereas the EC_{50} for ADM2 was 70 nM (Fig 2A). ADM and ADM2

---

**Fig 1.** Sequence alignment of CLR/RAMP receptor agonists. The sequence alignment includes CGRP (blue letters), adrenomedullin 14–52 (ADM14-52; red letters), adrenomedullin 2 (ADM2; black letters), as well as Agonists 1, 2 and 3. The N-terminal cysteines that form a disulfide ring are indicated by a yellow background. The region that is critical for the derivation of truncated ADM/ADM2 antagonists is indicated by a green background. The origin of individual residues in chimeric analogs is indicated by the color of residues. The N-terminal modifications, including palmitoylation (Pal-K or K(pal)), are indicated by brown letters.

https://doi.org/10.1371/journal.pone.0216996.g001
had low potencies on the activation of CLR/RAMP1 with EC$_{50}$ values >100 nM. On the other hand, CGRP had an EC$_{50}$ of 1.1–3.4 nM for CLR/RAMP1. By contrast, the EC$_{50}$ values for activating CLR/RAMP1 and 2 by the chimeric Agonist 1 was ~0.5 and 1 nM, respectively (Fig 2B). By contrast, the EC$_{50}$ of a corresponding analog without an acylation modification (Agonist 2) was 31 and 18 nM for CLR/RAMP1 and 2, respectively. Acylation modification of a wild-type ADM also increased the potency of the ADM analog (Agonist 3), but to a limited extent.

Because the activity of CGRP/ADM/ADM2 family peptides can be partly attributed to the degree of interaction between the C-terminal binding domain and the receptor extracellular domain (ECD) [65], we hypothesized that the binding domain of Agonist 1 could possess unique antagonistic activity toward CLR/RAMP receptors. In addition, because conjugation of a hydrophobic moiety at the N-terminus of CGRP8-37 improves receptor-interacting affinity, we appended a palmitic acid at the N-terminus of various chimeric analogs (Fig 3).

### Truncated chimeric ADM/ADM2 analogs potently inhibit CLR/RAMP1 and/or 2 signaling

CGRP8-37 and ADM22-52 are classic antagonists that exhibit strict preference for CLR/RAMP1 and 2, respectively (Fig 2). Analysis of receptor signaling at the antagonistic mode showed that ADM22-52 inhibits CGRP-mediated CLR/RAMP1 and ADM-stimulated CLR/RAMP2 signaling with IC$_{50}$ values of 6600 and 256 nM, respectively (Table 2, Fig 4A). On the other hand, CGRP8-37 had IC$_{50}$ values of 133 and >10000 nM, for CLR/RAMP1 and 2, respectively.

Analysis of an acylated 31-amino–acid ADM/ADM2 chimera (Antagonist 1–1, Table 2) and analogs with additional deletion at the junctional region of Antagonist 1–1 (i.e., Antagonists 1–2 [28 residues] and 1–3 [27 residues]) showed these chimeras exhibit potent antagonistic activity for both CLR/RAMP1 and 2 (Fig 4B). The IC$_{50}$ values of these chimeras for CLR/RAMP1 were 10-fold lower than that of CGRP8-37. Likewise, the IC$_{50}$ values for CLR/RAMP2 were 5- to 50-fold lower than that of ADM22-52. By contrast, a nonacylated analog of Antagonist 1–1 (Antagonist 1–4), a CGRP/ADM chimera (Antagonist 1–5), and an ADM/ADM2/
ADM chimera (Antagonist 1–6) showed lower bioactivity when compared with acylated ADM/ADM2 chimeras.

An ADM-derived motif is important for enhancing the antagonistic activity of chimeric analogs

To determine whether the enhanced activity of chimeric antagonists is affected by additional residue deletion, we studied analogs that contain further truncation at the junctional region of chimeric analogs (i.e., Antagonists 2–1 to 2–4 [17–22 residues]; Fig 3). These additional truncations had minimal effects on the antagonistic activity toward CLR/RAMP1 but reduced the antagonistic activity toward CLR/RAMP2 when compared to Antagonists 1–2 and 1–3 (Table 3, Fig 5). As such, these short analogs represent CLR/RAMP1-selective antagonists.

Of interest, sequence comparison showed the N-terminal ADM sequence of the 17-amino-acid Antagonist 2–4 is only one amino acid different from the corresponding region of ADM2 (VQKL in Antagonist 2–4 vs. VQNL in ADM2; highlighted with a green background in Fig 1),
suggesting this residue may play a role in shaping the bioactivity of Antagonist 2–4. Consistent with this hypothesis, substitution of the lysine residue in Antagonist 2–4 with an asparagine residue led to a 1000-fold reduction of the CLR/RAMP1-inhibitory activity (i.e., Antagonist 2–5).

Fig 3. Sequence alignment of chimeric antagonists. The sequence alignment includes CGRP8-37 (blue letters), ADM22-52 (red letters), Antagonists 1–1 to 1–6, Antagonists 2–1 to 2–5, and Antagonist 3–1. The origin of individual residues in chimeric analogs is indicated by the color of residues. The N-terminal modifications, including palmitoylation (Pal) and lysine-conjugated palmitoylation (Pal-K), are indicated by brown letters. Sequence gaps are indicated by dash lines.

Table 2. Antagonistic activity of chimeric CLR/RAMP receptor antagonists.

| Identity       | CLR/RAMP1  | CLR/RAMP2  |
|----------------|------------|------------|
|                | IC_{50} (nM) | Max Activity | IC_{50} (nM) | Max Activity |
|                | % of control |              | % of control |              |
| BIBN4096       | 0.05       | 105         | >100         | 0           |

Wild-type peptides

| Identity       | CLR/RAMP1  | CLR/RAMP2  |
|----------------|------------|------------|
| ADM22-52       | 6600       | 57         | 256         | 105         |
| CGRP8-37       | 133        | 95         | >10,000     | 15          |

Pan-specific chimeric antagonists

| Antagonist 1–1 | 9.9        | 101        | 47          | 100         |
| Antagonist 1–2 | 3.2        | 94         | 4.9         | 104         |
| Antagonist 1–3 | 7          | 93         | 7.1         | 100         |

Low-potency chimeric antagonists

| Antagonist 1–4 | 1123       | 106        | 289         | 101         |
| Antagonist 1–5 | 1878       | 99         | 117         | 100         |
| Antagonist 1–6 | 152        | 101        | 7.3         | 101         |

The antagonistic activity on CGRP-mediated CLR/RAMP1 and ADM-mediated CLR/RAMP2 signaling is described as IC_{50} and the maximum activity in % of a positive control. The potency of a small molecule CGRP antagonist, BIBN4096, is provided for comparison.

https://doi.org/10.1371/journal.pone.0216996.t002
In addition, studies of an ADM/CGRP chimera that contains an N-terminal ADM motif and a C-terminal 12-amino-acid fragment of CGRP (i.e., CGRP26-37; Antagonist 3–1, Table 3), which was known to have minimal bioactivity, showed this chimera has an IC$_{50}$ at the subnanomolar range for CLR/RAMP1, and an IC$_{50}$ that is >200 nM for CLR/RAMP2.

Chimeric unimolecular somatostatin-ADM antagonist analog exhibits dual activities on somatostatin and CLR/RAMP receptors

Because a targeted molecule could provide more specific therapeutic activity, ADM antagonists that contain a somatostatin receptor-interacting motif could sequester the antagonist to the neuroendocrine tumor (NET) microenvironment and be useful for the treatment of high-grade NETs which express high levels of somatostatin receptors. Analysis of a chimeric analog that contains the somatostatin analog octreotide ((D-Phe)$_4$(D-Trp)$_2$KCT) and a 28-amino-acid ADM antagonist sequence (K(Pal)VQKLAHQIYQFTDKDVAPRSKISPQGY) showed it possesses potent somatostatin receptor 2 (SSTR2)-activation activity and inhibitory activities on CLR/RAMP1 and 2 signaling (Table 4, Fig 6). The EC$_{50}$ for activating SSTR2 is similar to
that of somatostatin 1–28, and the inhibitory effects on CLR/RAMP1 and 2 signaling are at the same order as the pan-specific antagonistic analogs in Table 2.

### Table 3. Antagonistic activity of miniaturized CLR/RAMP receptor antagonists.

| Identity          | CLR/RAMP1 | CLR/RAMP2 |
|-------------------|-----------|-----------|
|                   | IC₅₀ (nM) | Max Activity % of control | IC₅₀ (nM) | Max Activity % of control |
| BIBN4096          | 0.05      | 105       | >100      | 0                       |
| Wild-type peptides|           |           |           |                          |
| ADM22-52          | 6600      | 57        | 256       | 105                     |
| CGRP8-37          | 133       | 95        | >10,000   | 15                      |
| Chimeric ADM/ADM2 analogs | | |
| Antagonist 2–1    | 7.3       | 95        | 61        | 100                     |
| Antagonist 2–2    | 4.7       | 94        | 50        | 101                     |
| Antagonist 2–3    | 6.7       | 95        | 64        | 103                     |
| Antagonist 2–4    | 3.8       | 98        | 462       | 101                     |
| Antagonist 2–5    | 3837      | 43        | >10,000   | 14                      |
| Chimeric ADM/CGRP analog | | |
| Antagonist 3–1    | <0.5      | 100       | 214       | 80                      |

The antagonistic activity on CGRP-mediated CLR/RAMP1 and ADM-mediated CLR/RAMP2 signaling is described as IC₅₀ and the maximum activity in % of a positive control. The potency of a small molecule CGRP antagonist, BIBN4096, is provided for comparison.  

https://doi.org/10.1371/journal.pone.0216996.t003

![Fig 5. Dose-response curves of miniaturized antagonists.](https://doi.org/10.1371/journal.pone.0216996.g005)

The inhibitory effects of Antagonists 2–1 to 2–5, and 3-1 on CLR/RAMP1 (upper panel) and 2 (lower panel) signaling are presented as dose-response curves in the presence of an EC₈₀ dose of CGRP or ADM, respectively.

**Discussion**

Based on the analysis of CLR/RAMP1 and 2 signaling, we showed that (1) acylated ADM/ADM2 chimeras exhibit antagonistic activities one to two orders stronger than those of CGRP8-37 and/or ADM22-52, and (2) chimeric octreotide-ADM antagonist analog exhibits
dual regulatory activities toward somatostatin and CLR/RAMP receptors. In addition, the data indicated that (1) N-terminal acylation and a lysine residue within the ADM motif of chimeric analogs are important for enhancing the antagonistic activity and (2) the sequence motif encompassing residues 22–40 of ADM is important for the interaction between chimeric ADM/ADM2 antagonists and CLR/RAMP2. Further characterization of these peptidomimetics may lead to the development of therapeutics that can better inhibit pathological CGRP and/or ADM signaling in patients.

Similar to calcitonin and amylin, CGRP/ADM/ADM2 family peptides have an N-terminal disulfide-bond ring followed by a helix region and an unstructured C-terminal region. These ligands presumably interact with the receptors via a two-domain model in which the C-terminal region binds the receptor ectodomain, while the N-terminal region activates the receptor [66]. Earlier studies have categorized the 37-amino-acid CGRP into four distinct domains: (1) a seven-residue ring structure, (2) an α-helix composed of residues 8–18, (3) a β-bend around residues 19–27, and (4) the C-terminal binding terminus [67–70]. Whereas Thr30, Val32, Gly33, and Phe37 in the CGRP C-terminus are key residues for CLR/RAMP1 interaction, residues 19–26 help maintain the structure at the C-terminus [69–75]. The deletion of N-terminal ring domain renders the truncated CGRP8-37 peptide a competitive antagonist with a 10-fold less affinity compared to CGRP [43, 76, 77]. Additional truncation of the CGRP8-37 sequence leads to further reduction of the bioactivity [68, 78]. Similarly, the main binding epitope of ADM is located at the C-terminal 8 amino acids, and the Ile47, Gly51, and Tyr52 residues are critical for CLR/RAMP2 binding [65, 79, 80]. In addition, recent structure analyses indicated that CGRP and ADM bind a common site on CLR, and an allosteric modulation of CLR and RAMP contacts cooperates to determine CGRP and ADM selectivity [81–83]. Structural analysis also indicates that ADM2 could act via a mechanism similar to that of ADM or CGRP [66, 84]. Specifically, CGRP was shown to form extensive interactions with CLR/RAMP1 with 61.5% of the peptide surface buried (Fig 7). The N-terminus of CGRP (Ala1-Val23) tightly interacts with the receptor core, whereas the C-terminal region (Phe27-Phe37) interacts with the CLR ECD and RAMP1. On the other hand, the structure at the linker region (Lys24-Asn26) between the N- and C-terminal receptor-interacting domains was poorly resolved, perhaps due to a high mobility of this region (Fig 7, the missing linker region is represented by a gap between Val23 and Phe27) [82]. It has been suggested that this linker region could be important for enabling the N-terminus to be buried within CLR and the C-terminus to interact with CLR ECD and RAMP1. Because the junctional regions in chimeric ADM/ADM2 antagonists correspond precisely to the linker region in CGRP, the “linker region” within select chimeric antagonists may allow the analog to better interact with CLR and RAMP1 and exert potent antagonistic activities.

Earlier studies have shown that (1) benzoylated derivatives of CGRP8-37 have substantially increased binding affinities for the CGRP receptor [62], and (2) lipidated CGRP8-37 and CGRP7-37 analogs have higher bioactivity [85]. These modifications may facilitate the interaction with CLR/RAMP receptors given a key feature of the peptide-binding sites in CLR/

**Table 4. The receptor-regulatory activity of a chimeric octreotide-ADM antagonist analog.**

| Identity               | CLR/RAMP1 | CLR/RAMP2 | SSTR2 |
|------------------------|-----------|-----------|-------|
|                        | IC50 (nM) | Max Activity | IC50 (nM) | Max Activity | EC50 (nM) | Max Activity |
| CGRP8-37               | 133       | 95        | >10,000 | 15           |
| ADM22-52               | 6600      | 57        | 256    | 105          |
| Somatostatin 1–28      |           |           | 6.8    | 102          |
| Octreotide-ADM antagonist analog | 2        | 102       | <0.5   | 87           | 17       | 117         |

https://doi.org/10.1371/journal.pone.0216996.004
RAMP1 is a hydrophobic patch extending from the base of CLR loop 4 to loop 3 \[62, 82\]. Alternatively, the hydrophobic modification may provide a better mimic of the membrane environment that a ligand encounters in association with a 7-transmembrane receptor \[34, 86, 87\]. Therefore, the enhanced bioactivity of chimeric antagonists could be partly attributed to these forces or conformational changes introduced by the N-terminal acylation together with the chimeric sequence.

**Fig 6.** Dose-response curves of a bifunctional octreotide-ADM antagonist analog. The stimulatory effects of somatostatin 1-28 and the bifunctional analog on somatostatin receptor 2 (SSTR2) signaling (left panel), and the inhibitory effects of the bifunctional analog on CLR/RAMP1 and 2 signaling (right panel) are presented as dose-response curves.

https://doi.org/10.1371/journal.pone.0216996.g006
CGRP is primarily released from C and Aδ sensory nerves, which are important for the modulation of inflammatory response, blood pressure, and auditory nerve development [34]. Excess CGRP release during neurogenic inflammation could lead to migraine headache, osteoarthritis pain, and other diseases [34, 35]. So far, four distinct approaches, including (1) peptide antagonists (e.g., CGRP8-37) [41–44], (2) small molecule antagonists (e.g., telcagepant and olcegepant) [45, 46], (3) anti-CGRP antibody [50], and (4) anti-RAMP1 antibody [50, 51] have been used to block CLR/RAMP1 signaling. Although several small molecule CGRP antagonists are effective in the treatment of migraine headache, they can lead to liver toxicity [52, 88–90]. On the other hand, several anti-CGRP/RAMP1 antibody-based therapies have been approved for the treatment of chronic migraine recently [39, 53, 54, 91–97]. However, a large fraction of migraine patients failed to respond to the anti-CGRP antibody therapies [36, 39, 51, 52, 55, 56]. Because antibody has a low volume of distribution, and the anti-CGRP antibodies mainly act by reducing the circulating level of CGRP or CGRP signaling in cells that are in close proximity of the vascular system [36, 96, 98, 99], there remains a large unmet medical

---

**Fig 7. Visualization of the linker region in the CGRP peptide, which corresponds to the “junctional” region of chimeric antagonists.** The interaction of chimeric antagonists with CLR/RAMP receptors could be similar to that between CGRP and the CGRP receptor complex as demonstrated by the RCSB protein data bank [PDB] structure 6E3Y [82]. The structure presented includes the CGRP (red), RAMP1 (pink) and CLR (yellow) components. The structure at the linker region of CGRP (Lys24-Asn26) was not resolved and is presented as a gap between the N- and C-terminal regions. The positions of Val23 and Phe27, which are next to the breakpoint as well as the C-terminal Phe37 of CGRP are indicated by arrows. The residues corresponding to Val23, Phe27, and Phe37 of CGRP in ADM and Antagonist 2–4 are presented next to the CGRP residues. Residues that were derived from ADM and ADM2 are indicated by red and black letters, respectively. https://doi.org/10.1371/journal.pone.0216996.g007
need of therapies for patients with severe migraine. Therefore, potent peptide antagonists, which have better access to nerve endings and a high safety margin, may represent alternative therapeutics for better control of CGRP signaling in patients [39, 100–102].

In addition, the peptide antagonist could be useful for the treatment of osteoarthritis pain. It has been shown that CGRP and its receptor increase in synovial cells, infrapatellar fat pad, and dorsal root ganglion neurons innervating knee joints in osteoarthritis patients [103–106]. In animal models, CGRP increases acute neurogenic inflammation and joint pain [107, 108]; whereas CGRP antagonists reduces osteoarthritis pain [61, 107, 109]. However, an anti-CGRP antibody (i.e., galcanezumab) failed to reduce osteoarthritis pain in patients [59, 60]. The lack of efficacy could be due to the inability of antibodies to reduce CGRP in the synovial joint to a therapeutic level. Therefore, peptide antagonists, which have better access to nerve endings in the joints, may provide an alternative path for the development of anti-osteoarthritis pain therapy. Furthermore, because ADM signaling has been implicated in the regulation of inflammatory heat hyperalgesia and spinal glial activation [110–113], the pan-specific antagonists described here may be useful for spontaneous blockage of CGRP- and ADM-mediated pain responses.

ADM plays an important role in the regulation of angiogenesis and exhibits anti-inflammatory effects. Earlier studies have shown ADM22-52, small molecule antagonist, anti-ADM antibody, and anti-CLR/RAMP antibodies block the growth and/or metastasis of tumor xenografts in animal models [25, 26, 29, 43, 47, 49, 57, 114]. Because known peptide antagonists have low potency and short half-life, and because the antibody-based strategy has a low volume of distribution, the pan-specific antagonists may represent promising candidates for the treatment of tumor angiogenesis/metastasis and for improving tumor immune-surveillance. Among the antagonistic analogs, the bifunctional unimolecular octreotide-ADM antagonist analog could be particularly useful for the treatment of high-grade NETs. The bifunctional analog could use the NET cell’s unique characteristics (i.e., the expression of somatostatin receptors) to target the ADM antagonist to the NET microenvironment and increase tumor accumulation. As such, the bifunctional analog could have more potent anti-tumor growth/metastasis activities compared to current somatostatin analog-based therapies. It is also important to note that the bifunctional analog could represent a prime candidate for the development of a tyrosine kinase receptor-independent antiangiogenesis therapy for other cancers. For example, the bifunctional analog could be particularly useful for the treatment of castration-resistant prostate cancer. Emerging evidences have shown that (1) neuroendocrine differentiation (NED) secondary to androgen deprivation therapy (ADT) occurs frequently in metastatic castrate-resistant prostate cancer [115], and (2) somatostatin analogs increase the therapeutic window of ADT in patients with castration-resistant prostate cancer [116, 117].

Acknowledgments
We thank the technical assistance of Dr. James Chow (Lifetein LLC).

Author Contributions
Conceptualization: Sheau Yu Teddy Hsu.
Data curation: Chia Lin Chang, Sheau Yu Teddy Hsu.
Formal analysis: Chia Lin Chang, Sheau Yu Teddy Hsu.
Funding acquisition: Sheau Yu Teddy Hsu.
Investigation: Sheau Yu Teddy Hsu.
Methodology: Chia Lin Chang, Sheau Yu Teddy Hsu.
Validation: Sheau Yu Teddy Hsu.
Writing – original draft: Chia Lin Chang.
Writing – review & editing: Sheau Yu Teddy Hsu.

References

1. Michibata H, Mukoyama M, Tanaka I, Suga S, Nakagawa M, Ishibashi R, et al. Autocrine/paracrine role of adrenomedullin in cultured endothelial and mesangial cells. Kidney Int. 1998; 53(4):979–85. Epub 1998/04/29. https://doi.org/10.1111/j.1523-1755.1998.00855.x PMID: 9551407.
2. Kitamura K, Ichiki Y, Tanaka M, Kawamoto M, Emura J, Sakakibara S, et al. Immunoreactive adrenomedullin in human plasma. FEBS Lett. 1994; 341(2–3):288–90. Epub 1994/03/21. 0014-5793(94)00474-5 [pii] PMID: 8137955.
3. Hinson JP, Kapas S, Smith DM. Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev. 2000; 21(2):138–67. https://doi.org/10.1210/edrv.21.2.0396 PMID: 10782362.
4. Roh J, Chang CL, Bhalla A, Klein C, Hsu SY. Intermedin is a calcitonin/CGRP family peptide acting through the CRLR/RAMP receptor complexes. J Biol Chem. 2004; 279(8):7264–74. https://doi.org/10.1074/jbc.M305332200 PMID: 14615490.
5. Takei Y, Inoue K, Ogoshi M, Kawahara T, Bannai H, Miyano S. Identification of novel adrenomedullin in mammals: a potent cardiovascular and renal regulator. FEBS Lett. 2004; 556(1–3):53–8. Epub 2004/01/07. S0014-5793(03)01368-1 [pii] PMID: 14706825.
6. McLaughie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature. 1998; 393(6683):333–9. https://doi.org/10.1038/30666 PMID: 9620797.
7. Bell D, McDermott BJ. Intermedin (adrenomedullin-2): a novel counter-regulatory peptide in the cardiovascular and renal systems. Br J Pharmacol. 2008; 153 Suppl 1:S247–62. Epub 2007/10/30. 10.1038/sj.bjp.0707494 [pii] PMID: 17965749.
8. Muff R, Leuthardt K, Buhlmann N, Foord SM, Fischer JA, Born W. Receptor activity modifying proteins regulate the activity of a calcitonin gene-related peptide receptor in rabbit aortic endothelial cells. FEBS Lett. 1998; 441(3):366–8. Epub 1999/01/19. S0014-5793(98)01587-7 [pii] PMID: 9891972.
9. Dunworth WP, Fritz-Six KL, Caron KM. Adrenomedullin stabilizes the lymphatic endothelial barrier in vitro and in vivo. Peptides. 2008; 29(12):2243–9. Epub 2008/10/22. https://doi.org/10.1016/j.peptides.2008.09.009 PMID: 18929609; PubMed Central PMCID: PMC2639781.
10. Dackor RT, Fritz-Six K, Dunworth WP, Gibbons CL, Smithies O, Caron KM. Hydrops fetalis, cardiovascular defects, and embryonic lethality in mice lacking the calcitonin receptor-like receptor gene. Mol Cell Biol. 2006; 26(7):2511–8. https://doi.org/10.1128/MCB.26.7.2511-2518.2006 PMID: 16537897.
11. Koyama T, Sakurai T, Kamiyoshi A, Ichikawa-Shindo Y, Kawate H, Shindo T. Adrenomedullin-RAMP2 System in Vascular Endothelial Cells. J Atheroscler Thromb. 2015; 22(7):647–53. Epub 2015/06/05. https://doi.org/10.5551/jat.29967 PMID: 26040754.
12. Koyama T, Ochoa-Calilejero L, Sakurai T, Kamiyoshi A, Ichikawa-Shindo Y, Inuma N, et al. Vascular Endothelial Adrenomedullin-RAMP2 System Is Essential for Vascular Integrity and Organ Homeostasis. Circulation. 2013; 127(7):842–53. Epub 2013/01/29. https://doi.org/10.1161/CIRCULATIONAHA.112.007956 CIRCULATIONAHA.112.007956 [pii] PMID: 23355623.
13. Smith RS Jr., Gao L, Bledsoe G, Chao L, Chao J. Intermedin is a new angiogenic growth factor. Am J Physiol Heart Circ Physiol. 2009; 297(3):H1040–7. Epub 2009/07/14. 00404.2009 [pii] https://doi.org/10.1152/ajpheart.00404.2009 PMID: 19592612.
14. Zheng S, Li W, Xu M, Bai X, Zhou Z, Han J, et al. Calcitonin gene-related peptide promotes angiogenesis via AMP-activated protein kinase. Am J Physiol Cell Physiol. 2010; 299(6):C1485–92. Epub 2010/10/01. ajpcell.0073.2010 [pii] https://doi.org/10.1152/ajpcell.0073.2010 PMID: 20881236.
15. Imuro S, Shindo T, Moriyama N, Amaki T, Niu P, Takeda N, et al. Angiogenic effects of adrenomedullin in ischemia and tumor growth. Circ Res. 2004; 95(4):415–23. Epub 2004/07/10. https://doi.org/10.1161/01.RES.0000138018.61065.d1 PMID: 15242974.
16. Wilson C, Nikiteno LL, Sargent IL, Rees MC. Adrenomedullin: multiple functions in human pregnancy. Angiogenesis. 2004; 7(3):203–12. Epub 2004/12/21. https://doi.org/10.1007/s10456-004-4183-5 PMID: 15609875.
17. Tsatsaris V, Tarrade A, Merviel P, Gareil JM, Segond N, Julienne A, et al. Calcitonin gene-related peptide (CGRP) and CGRP receptor expression at the human implantation site. J Clin Endocrinol Metab. 2002; 87(9):4383–90. Epub 2002/09/06. https://doi.org/10.1210/jc.2002-020138 PMID: 12213903.

18. Dong YL, Reddy DM, Green KE, Chauhan MS, Wang HQ, Nagamani M, et al. Calcitonin gene-related peptide (CALCA) is a proangiogenic growth factor in the human placental development. Biol Reprod. 2007; 76(5):892–9. Epub 2007/02/03. bioireprod.106.059089 [pii] https://doi.org/10.1095/biorenprod.106.059089 PMID: 17267696.

19. Zhang X, Green KE, Yallampalli C, Dong YL. Adrenomedullin enhances invasion by trophoblast cell lines. Biol Reprod. 2005; 73(4):619–26. Epub 2005/05/27. bioireprod.105.040436 [pii] https://doi.org/10.1095/biorenprod.105.040436 PMID: 15917349.

20. Dong YL, Vegiraju S, Chauhan M, Yallampalli C. Expression of calcitonin gene-related receptor components, calcitonin receptor-like receptor and receptor activity modifying protein 1, in the rat placenta during pregnancy and their cellular localization. Mol Hum Reprod. 2003; 9(8):481–90. Epub 2003/07/03. https://doi.org/10.1093/ molehr/gag058 PMID: 12837925.

21. Cormier-Regard S, Nguyen SV, Claycomb WC. Adrenomedullin gene expression is developmentally regulated and induced by hypoxia in rat ventricular cardiac myocytes. J Biol Chem. 1998; 273(28):17787–92. Epub 1998/07/04. https://doi.org/10.1074/jbc.273.28.17787 PMID: 9651380.

22. Garayoa M, Martinez A, Lee S, Pio R, An WG, Neckers L, et al. Hypoxia-inducible factor-1 (HIF-1) up-regulates adrenomedullin expression in human tumor cell lines during oxygen deprivation: a possible promotion mechanism of carcinogenesis. Mol Endocrinol. 2000; 14(6):848–62. Epub 2000/06/10. https://doi.org/10.1210/mend.14.6.0473 PMID: 10847587.

23. Marinoni E, Pacioni K, Sambucini A, Moscarini M, Letizia C, R DII. Regulation by hypoxia of adrenomedullin output and expression in human trophoblast cells. Eur J Obstet Gynecol Reprod Biol. 2011; 154(2):146–50. Epub 2010/11/26. S0301-2115(10)00507-S [pii] https://doi.org/10.1016/j.ejogrb.2010.10.013 PMID: 21094578.

24. Albertin G, Sorato E, Oselladore B, Mascarin A, Tortorella C, Guidolin D. Involvement of vascular endothelial growth factor signaling in CLR/RAMP1 and CLR/RAMP2-mediated pro-angiogenic effect of intermedin on human vascular endothelial cells. Int J Mol Med. 2010; 26(2):289–94. Epub 2010/07/03. PMID: 20596610.

25. Ochoa-Callejero L, Garcia-Sanmartin J, Martinez-Herrero S, Rubio-Mediavilla S, Narro-Iniguez J, Martinez A. Small molecules related to adrenomedullin reduce tumor burden in a mouse model of colitis-associated colon cancer. Sci Rep. 2017; 7(1):17488. Epub 2017/12/14. https://doi.org/10.1038/s41598-017-17573-x PMID: 29235493.

26. Wang LJ, Xiao F, Kong LM, Wang DN, Li HY, Wei YG, et al. Intermedin Enhances the Vascular Lumen by Inducing the Quiescent Endothelial Cell Proliferation. Arterioscler Thromb Vasc Biol. 2018; 38
34. Russell FA, King R, Smillie SJ, Kodji X, Brain SD. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev. 2014; 94(4):1099–142. Epub 2014/10/08. 94/4/1099 [pii] https://doi.org/10.1152/physrev.00034.2013 PMID: 25287861.

35. Maggi CA. Tachykinins and calcitonin gene-related peptide (CGRP) as co-transmitters released from peripheral endings of sensory nerves. Prog Neurobiol. 1995; 45(1):1–98. Epub 1995/01/01. 0301-0082(94)E0017-B [pii]. PMID: 27716258.

36. Deen M, Correnti E, Kamm K, Kelderman T, Papetti L, Rubio-Beltran E, et al. Blocking CGRP in migraine patients—a review of pros and cons. J Headache Pain. 2017; 18(1):96. Epub 2017/09/28. https://doi.org/10.1186/s10194-017-0807-1 [pii]. PMID: 28948500.

37. Schuster NM, Rapoport AM. New strategies for the treatment and prevention of primary headache disorders. Nat Rev Neurol. 2016; 12(11):635–50. Epub 2016/10/28. nrneurol.2016.143 [pii] https://doi.org/10.1038/nrneurol.2016.143 PMID: 27786243.

38. Schou WS, Ashina S, Amin FM, Goadsby PJ, Ashina M. Calcitonin gene-related peptide and pain: a systematic review. J Headache Pain. 2017; 18(1):34. Epub 2017/03/18. https://doi.org/10.1186/s10194-017-0741-2 [pii]. PMID: 28303458.

39. Tso AR, Goadsby PJ. Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention? Curr Treat Options Neurol. 2017; 19(8):27. Epub 2017/06/28. https://doi.org/10.1007/s11940-017-0463-4 [pii]. PMID: 28653227.

40. Cornish J, Callon KE, Bava U, Coy DH, Mulvey TB, Murray MA, et al. Systemic administration of adrenomedullin(27–52) increases bone volume and strength in male mice. J Endocrinol. 2001; 170(1):251–7. PMID: 11431158.

41. Taylor CK, Abel PW, Hulce M, Smith DD. N-terminal bis-(2-chloroethyl)amino and fluorosulphonyl analogues of calcitonin gene-related peptide(8–37): irreversible antagonists at calcitonin gene-related peptide receptors. Chem Biol Drug Des. 2007; 70(3):216–26. Epub 2007/08/28. JPP558 [pii] https://doi.org/10.1111/j.1747-0285.2007 .00558.x PMID: 17718716.

42. Taylor CK, Smith DD, Hulce M, Abel PW. Pharmacological characterization of novel alpha-Calcitonin Gene-Related Peptide (CGRP) receptor peptide antagonists that are selective for human CGRP receptors. J Pharmacol Exp Ther. 2006; 319(2):749–57. Epub 2006/07/29. jpet.106.108316 [pii] https://doi.org/10.1124/jpet.106.108316 PMID: 16873605.

43. Chiba T, Yamaguchi A, Yamatani T, Nakamura A, Morishita T, Inui T, et al. Calcitonin gene-related peptide receptor antagonist human CGRP-(8–37). Am J Physiol. 1989; 256(2 Pt 1):E331–5. https://doi.org/10.1152/ajpendo.1989.256.2.E331 PMID: 2537579.

44. Miranda LP, Holder JR, Shi L, Bennett B, Aral J, Gegg CV, et al. Identification of potent, selective, and metabolically stable peptide antagonists to the calcitonin gene-related peptide (CGRP) receptor. J Med Chem. 2008; 51(24):7889–97. Epub 2008/12/05. https://doi.org/10.1021/jm8009288 [pii]. PMID: 19053766.

45. Doods H, Hallermyer G, Wu D, Entzeroth M, Rudolf K, Engel W, et al. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol. 2000; 129(3):420–3. Epub 2000/03/11. https://doi.org/10.1038/sj.bjp.0703110 PMID: 10711399.

46. Moore EL, Salvatore CA. Targeting a family B GPCR/RAMP receptor complex: CGRP receptor antagonists and migraine. Br J Pharmacol. 2012; 166(1):66–78. Epub 2011/08/30. https://doi.org/10.1111/j.1476-5381.2011.01633.x PMID: 21871919; PubMed Central PMCID: PMC3415638.

47. Kaafarani I, Fernandez-Sauze S, Berenguer C, Chinot O, Delfino C, Dussert C, et al. Targeting adrenomedullin receptors with systemic delivery of neutralizing antibodies inhibits tumor angiogenesis and suppresses growth of human tumor xenografts in mice. FASEB J. 2009; 23(10):3424–35. Epub 2009/06/24. fja.08-127852 [pii] https://doi.org/10.1096/fj.08-127852 PMID: 19546305.

48. Deville JL, Salas S, Figarella-Braga D, Ouafik L, Daniel L. Adrenomedullin as a therapeutic target in angiogenesis. Expert Opin Ther Targets. 2010; 14(10):1059–72. Epub 2010/09/18. https://doi.org/10.1517/14728222.2010.522328 PMID: 20846006.

49. Khalfawi-Bendriss G, Dussault N, Fernandez-Sauze S, Berenguer-Daize C, Sigaud R, Delfino C, et al. Adrenomedullin blockade induces regression of tumor neovessels through interference with vascular endothelial-cadherin signalling. Oncotarget. 2015; 6(10):7536–53. Epub 2015/04/30. 3167 [pii] https://doi.org/10.18632/oncotarget.3167 PMID: 25924235.

50. Bign ME, Walter S, Rapoport AM. Therapeutic antibodies against CGRP or its receptor. Br J Clin Pharmacol. 2015; 79(6):886–95. Epub 2015/01/24. https://doi.org/10.1111/bcp.12591 PMID: 25614243.

51. Shi L, Lehto SG, Zhu DX, Sun H, Zhang J, Smith BP, et al. Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide
52. Verheggen R, Bumann K, Kaumann AJ. BIBN4096BS is a potent competitive antagonist of the relaxant effects of alpha-CGRP on human temporal artery: comparison with CGRP(8–37). Br J Pharmacol. 2002; 136(1):120–6. Epub 2002/04/27. https://doi.org/10.1038/sj.bjp.0704682 PMID: 11976276.

53. Choy M. Pharmaceutical Approval Update. P T. 2018; 43(8):461–2. Epub 2018/08/14. PMID: 30100686.

54. Tepper SJ. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment. Headache. 2018. Epub 2018/09/23. https://doi.org/10.1111/head.13379 PMID: 30242830.

55. Zeller J, Poulsen KT, Sutton JE, Abdiche YN, Collier S, Chopra R, et al. CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat. Br J Pharmacol. 2008; 155(7):1093–103. Epub 2008/09/09. bjp2008334 [pii] https://doi.org/10.1038/bjp.2008.334 PMID: 18776916.

56. Aiyar N, Daines RA, Disa J, Chambers PA, Sauermech CF, Quiniou M, et al. Pharmacology of SB-273779, a nonpeptide calcitonin gene-related peptide 1 receptor antagonist. J Pharmacol Exp Ther. 2001; 296(3):768–75. Epub 2001/02/22. PMID: 11181905.

57. Tsuchiya K, Hida K, Hida Y, Muraki C, Ogha N, Akino T, et al. Adrenomedullin antagonist suppresses tumor formation in renal cell carcinoma through inhibitory effects on tumor endothelial cells and endothelial progenitor mobilization. Int J Oncol. 2010; 36(6):1379–86. Epub 2010/04/30. PMID: 20428760.

58. Nouguere E, Berenguer C, Garcia S, Bennani B, Delfino C, Nanni I, et al. Expression of adrenomedullin in human colorectal tumors and its role in cell growth and invasion in vitro and in xenograft growth in vivo. Cancer Med. 2013; 2(2):196–207. Epub 2013/05/02. https://doi.org/10.1002/cam4.51 PMID: 23634287.

59. Jin Y, Smith C, Monteith D, Brown R, Camporeale A, McNearney T, et al. LY2951742, a monoclonal antibody against CGRP, failed to reduce signs and symptoms of knee osteoarthritis. Osteoarthritis Cartilage. 2016; 24:S50.

60. Jin Y, Smith C, Monteith D, Brown R, Camporeale A, McNearney TA, et al. CGRP blockade by galcanezumab was not associated with reductions in signs and symptoms of knee osteoarthritis in a randomized clinical trial. Osteoarthritis Cartilage. 2018. Epub 2018/09/22. S1063-4584(18)31459-6 [pii] https://doi.org/10.1016/j.joca.2018.08.019 PMID: 30240937.

61. Benschop RJ, Collins EC, Darling RJ, Allan BW, Leung D, Conner EM, et al. Development of a novel antibody to calcitonin gene-related peptide for the treatment of osteoarthritis-related pain. Osteoarthritis Cartilage. 2014; 22(4):578–85. Epub 2014/02/11. S1063-4584(14)00033-8 [pii] https://doi.org/10.1016/j.joca.2014.01.009 PMID: 24508775.

62. Smith DD, Saha S, Fang G, Schaffert C, Waugh DJ, Zeng W, et al. Modifications to the N-terminus but not the C-terminus of calcitonin gene-related peptide (8–37) produce antagonists with increased affinity. J Med Chem. 2003; 46(12):2427–35. Epub 2003/05/30. https://doi.org/10.1021/jm020507f PMID: 12773046.

63. Bradley J, McLoughlin D. Use of the DiscoveRx Hit hunter cAMPII assay for direct measurement of cAMP in Gs and Gi GPCRs. Methods Mol Biol. 2009; 552:171–9. Epub 2009/06/11. https://doi.org/10.1007/978-1-60327-317-6_12 PMID: 19513649.

64. Andressen KV, Feigh M, Hjuler ST, Gydesen S, Henriksen JE, Beck-Nielsen H, et al. A novel oral dual amylin and calcitonin receptor agonist (KBP-042) exerts antiobesity and antiadipogenic effects in rats. Am J Physiol Endocrinol Metab. 2014; 307(1):E24–33. Epub 2014/05/08. https://doi.org/10.1152/ajpendo.00121.2014 PMID: 24801386.

65. ter Haar E, Koth CM, Abdul-Manan N, Swenson L, Coll JT, Lippke JA, et al. Crystal structure of the ectodomain complex of the CGRP receptor, a class-B GPCR, reveals the site of drug antagonism. Structure. 2010; 18(9):1083–93. Epub 2010/09/10. S0969-2126(10)00265-0 [pii] https://doi.org/10.1016/j.str.2010.05.014 PMID: 20826335.

66. Partnher C, Reedtz-Runge S, Rudolph R, Stubbs MT. Passing the baton in class B GPCRs: peptide hormone activation via helix induction? Trends Biochem Sci. 2009; 34(6):303–10. Epub 2009/05/19. S0968-0009(09)00072-3 [pii] https://doi.org/10.1016/j.tibs.2009.02.004 PMID: 19446460.

67. Conner AC, Hay DL, Howitt SG, Kilk K, Langel U, Wheatley M, et al. Interaction of calcitonin-gene-related peptide with its receptors. Biochem Soc Trans. 2002; 30(4):451–5. Epub 2002/08/28. https://doi.org/10.1042/ PMID: 12196113.

68. Rovero P, Giuliani S, Maggi CA. CGRP antagonist activity of short C-terminal fragments of human alpha CGRP, CGRP(23–37) and CGRP(19–37). Peptides. 1992; 13(5):1025–7. Epub 1992/09/01. 0196-9781(92)90067-D [pii] PMID: 1336185.
69. Breeze AL, Harvey TS, Bazzo R, Campbell ID. Solution structure of human calcitonin gene-related peptide by 1H NMR and distance geometry with restrained molecular dynamics. Biochemistry. 1991; 30(2):575–82. Epub 1991/01/15. PMID: 1988044.

70. Carpenter KA, Schmidt R, von Mentzer B, Haglund U, Roberts E, Walpole C. Turn structures in CGRP C-terminal analogues promote stable arrangements of key residue side chains. Biochemistry. 2001; 40(28):8317–25. Epub 2001/07/11. biol012860 [pii]. PMID: 11444978.

71. Boulanger Y, Khiat A, Larroque A, Fourrier A, St-Pierre S. Structural comparison of alanine-substituted analogues of the calcitonin gene-related peptide 8–37. Importance of the C-terminal segment for antagonistic activity. Int J Pept Protein Res. 1996; 47(6):477–83. Epub 1996/06/01. PMID: 8836775.

72. Poyner DR, Soomets U, Howitt SG, Langel U. Structural determinants for binding to CGRP receptors expressed by human SK-N-MC and Col 29 cells: studies with chimeric and other peptides. Br J Pharmacol. 1998; 124(8):1659–66. Epub 1998/10/02. https://doi.org/10.1038/sj.bjp.0702032 PMID: 9756381.

73. Howitt SG, Kilk K, Wang Y, Smith DM, Langel U, Poyner DR. The role of the 8–18 helix of CGRP8-37 in mediating high affinity binding to CGRP receptors; coulombic and steric interactions. Br J Pharmacol. 2003; 138(2):325–32. Epub 2003/01/24. https://doi.org/10.1038/sj.bjp.0705040 PMID: 12540523.

74. Rist B, Entzeroth M, Beck-Sickinger AG. From micromolar to nanomolar affinity: a systematic approach to identify the binding site of CGRP at the human calcitonin gene-related peptide 1 receptor. J Med Chem. 1998; 41(1):117–23. Epub 1998/01/23. https://doi.org/10.1021/jm970533f PMID: 9438028.

75. Boeglin D, Hamdan FF, Melendez RE, Cluzeau J, Laperriere A, Heroux M, et al. Calcitonin gene-related peptide analogues with aza and indolizidine amino acid residues reveal conformational requirements for antagonist activity at the human calcitonin gene-related peptide 1 receptor. J Med Chem. 2007; 50(6):1401–8. Epub 2007/02/27. https://doi.org/10.1021/jm061343w PMID: 17319653.

76. Watkins HA, Rathbone DL, Barwell J, Hay DL, Poyner DR. Structure-activity relationships for alpha-calcalcinin gene-related peptide. Br J Pharmacol. 2013; 170(7):1308–22. Epub 2012/11/29. https://doi.org/10.1111/bph.12072 PMID: 23186257.

77. Dennis T, Fourrier A, Cadieux A, Pomerleau F, Jolicoeur FB, St Pierre S, et al. hCGRP8-37, a calcitonin gene-related peptide antagonist revealing calcitonin gene-related peptide receptor heterogeneity in brain and periphery. J Pharmacol Exp Ther. 1990; 294(1):123–8. Epub 1990/07/01. PMID: 2164085.

78. Lang M, De Pol S, Baldauf C, Hofmann HU, Reiser O, Beck-Sickinger AG. Identification of the key residue of calcitonin gene related peptide (CGRP) 27–37 to obtain antagonists with picomolar affinity at the CGRP receptor. J Med Chem. 2006; 49(2):616–24. Epub 2006/02/20. https://doi.org/10.1021/jm050613s PMID: 16420047.

79. Kusano S, Kuikamoto-Niino M, Hino N, Ohsawa N, Okuda K, Sakamoto K, et al. Structural basis for extracellular interactions between calcitonin receptor-like receptor and receptor activity-modifying protein 2 for adrenomedullin-specific binding. Protein Sci. 2012; 21(2):199–210. Epub 2011/11/22. https://doi.org/10.1002/pro.2003 PMID: 22102369.

80. Watkins HA, Au M, Bobby R, Archbold JK, Abdul-Manan N, Moore JM, et al. Identification of key residues involved in adrenomedullin binding to the AM1 receptor. Br J Pharmacol. 2013; 169(1):143–55. Epub 2013/01/29. https://doi.org/10.1111/bph.12118 PMID: 23351143.

81. Woolley MJ, Watkins HA, Taddesse B, Karakkuluku ZG, Barwell J, Smith KJ, et al. The role of ECL2 in CGRP receptor activation: a combined modelling and experimental approach. J R Soc Interface. 2013; 10(88):20130589. Epub 2013/09/21. rsif.2013.0589 pii https://doi.org/10.1098/rsif.2013.0589 PMID: 24047872.

82. Liang YL, Khoshouei M, Deganutti G, Glukhova A, Koole C, Peat TS, et al. Cryo-EM structure of the active, Gs-protein complexed, human CGRP receptor. Nature. 2018; 561(7724):492–7. Epub 2018/09/14. https://doi.org/10.1038/s41586-018-0535-y PMID: 30209400.

83. Lee SM, Hay DL, Pioszak AA. Calcitonin and Amylin Receptor Peptide Interaction Mechanisms: INSIGHTS INTO PEPTIDE-BINDING MODES AND ALLOSTERIC MODULATION OF THE CALCITONIN RECEPTOR BY RECEPTOR ACTIVITY-MODIFYING PROTEINS. J Biol Chem. 2016; 291(16):8686–700. Epub 2016/02/21. M15.713628 [pii] https://doi.org/10.1074/jbc.M115.713628 PMID: 26895962.

84. Roekrakasse AM, Booe JM, Lee SM, Warner ML, Pioszak AA. Structure-function analyses reveal a triple beta-turn receptor-bound conformation of adrenomedullin 2/intermedin and enable peptide antagonist design. J Biol Chem. 2018. Epub 2018/08/25. RA118.005062 [pii] https://doi.org/10.1074/jbc. RA118.005062 PMID: 30139742.

85. Williams ET, Harris PWR, Jamaluddin MA, Loomes KM, Hay DL, Brimble MA. Solid-Phase Thiol-Ene Lipidation of Peptides for the Synthesis of a Potent CGRP Receptor Antagonist. Angew Chem Int Ed
86. Nanga RP, Brender JR, Vivekanandan S, Ramamoorthy A. Structure and membrane orientation of IAPP in its natively amidated form at physiological pH in a membrane environment. Biochim Biophys Acta. 2011; 1808(10):2337–42. Epub 2011/07/05. S0005-2736(11)00184-2 [pii] https://doi.org/10.1016/j.bbamem.2011.06.012 PMID: 21723249.

87. Perez-Castells J, Martin-Santamaria S, Nieto L, Ramos A, Martinez A, Pascual-Teresa B, et al. Structure of micelle-bound adrenomedullin: a first step toward the analysis of its interactions with receptors and small molecules. Biopolymers. 2012; 97(1):45–53. Epub 2011/08/11. https://doi.org/10.1002/bip.21700 PMID: 21830197.

88. Negro A, Lionetto L, Simmaco M, Martelletti P. CGRP receptor antagonists: an expanding drug class for acute migraine? Expert Opin Investig Drugs. 2012; 21(6):807–18. Epub 2012/04/20. https://doi.org/10.1517/13543784.2012.681044 PMID: 22512641.

89. Durham PL, Vause CV. Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine. CNS Drugs. 2010; 24(7):539–48. Epub 2010/05/04. https://doi.org/10.2165/11534920-000000000-00000 PMID: 20433208.

90. Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, et al. Calcitonin gene-related peptide antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004; 350(11):1104–10. Epub 2004/03/12. https://doi.org/10.1056/NEJMoa030505 PMID: 15014183.

91. Hendrikse ER, Bower RL, Hay DL, Walker CS. Molecular studies of CGRP and the CGRP family of peptides in the central nervous system. Cephalalgia. 2018; 333102418765787. Epub 2018/03/24. https://doi.org/10.1177/0333102418765787 PMID: 29566540.

92. Russo AF. CGRP gene-related peptide (CGRP): a new target for migraine. Annu Rev Pharmacol Toxicol. 2012; 55:533–52. Epub 2012/04/24. https://doi.org/10.1146/annurev-pharmtox-010814-124701 PMID: 2340934.

93. Jacobs B, Dussor G. Neurovascular contributions to migraine: Moving beyond vasodilation. Neuroscience. 2016; 338:130–44. Epub 2016/10/27. S0306-4522(16)30242-1 [pii] https://doi.org/10.1016/j.neuroscience.2016.06.012 PMID: 27312704.

94. Feistel S, Albrecht S, Messlinger K. The calcitonin gene-related peptide receptor antagonist MK-8825 decreases spinal trigeminal activity during nitroglycerin infusion. J Headache Pain. 2013; 14:93. Epub 2013/11/22. 1129-2377-14-93 [pii] https://doi.org/10.1186/1129-2377-14-93 PMID: 24256609.

95. Michot B, Kayser V, Hamon M, Bourgoind S. CGRP receptor blockade by MK-8825 alleviates alldynia in infraorbital nerve-ligated rats. Eur J Pain. 2015; 19(2):281–90. Epub 2014/11/06. https://doi.org/10.1002/ejp.616 PMID: 25370954.

96. Taniguchi A, Ishikawa T, Miyagi M, Kamoda H, Sakuma Y, Oikawa Y, et al. Decreased calcitonin gene-related peptide expression in the dorsal root ganglia of TNF-deficient mice in a monoiodoacetate-induced knee osteoarthritis model. Int J Clin Exp Pathol. 2015; 8(10):12967–71. Epub 2016/01/02. PMID: 26722492.
104. Minatani A, Uchida K, Inoue G, Takano S, Aikawa J, Miyagi M, et al. Activation of calcitonin gene-related peptide signaling through the prostaglandin E2-EP1/EP2/EP4 receptor pathway in synovium of knee osteoarthritis patients. J Orthop Surg Res. 2016; 11(1):117. Epub 2016/10/19. https://doi.org/10.1186/s13018-016-0460-4 [pii]. PMID: 27751171.

105. Takano S, Uchida K, Inoue G, Minatani A, Miyagi M, Aikawa J, et al. Increase and regulation of synovial calcitonin gene-related peptide expression in patients with painful knee osteoarthritis. J Pain Res. 2017; 10:1099–104. Epub 2017/05/27. https://doi.org/10.2147/JPR.S135939 PMID: 28546767.

106. Aikawa J, Uchida K, Takano S, Inoue G, Iwase D, Miyagi M, et al. Regulation of calcitonin gene-related peptide expression through the COX-2/mPGES-1/PGE2 pathway in the infrapatellar fat pad in knee osteoarthritis. Lipids Health Dis. 2018; 17(1):215. Epub 2018/09/13. https://doi.org/10.1186/s12944-018-0864-8 [pii]. PMID: 30205824.

107. Walsh DA, Mapp PI, Kelly S. Calcitonin gene-related peptide in the joint: contributions to pain and inflammation. Br J Clin Pharmacol. 2015; 80(5):965–78. Epub 2015/04/30. https://doi.org/10.1111/bcp.12669 PMID: 25923821.

108. Yu D, Liu F, Liu M, Zhao X, Wang X, Li Y, et al. The inhibition of subchondral bone lesions significantly reversed the weight-bearing deficit and the overexpression of CGRP in DRG neurons, GFAP and Iba-1 in the spinal dorsal horn in the monosodium iodoacetate induced model of osteoarthritis pain. PLoS One. 2013; 8(10):e77824. Epub 2013/11/10. https://doi.org/10.1371/journal.pone.0077824 PMID: 24204985.

109. Bullock CM, Wooley P, Bennett A, Mobasher A, Dickerson I, Kelly S. Peripheral calcitonin gene-related peptide receptor activation and mechanical sensitization of the joint in rat models of osteoarthritis pain. Arthritis Rheumatol. 2014; 66(8):2188–200. Epub 2014/04/11. https://doi.org/10.1002/art.38656 PMID: 24719311.

110. Zeng X, Lin MY, Wang D, Zhang Y, Hong Y. Involvement of adrenomedullin in spinal glial activation following chronic administration of morphine in rats. Eur J Pain. 2014; 18(9):1323–32. Epub 2014/03/26. https://doi.org/10.1002/ejp.493.e11 PMID: 24664661.

111. Wang D, Chen P, Li Q, Quirion R, Hong Y. Blockade of adrenomedullin receptors reverses morphine tolerance and its neurochemical mechanisms. Behav Brain Res. 2011; 221(1):83–90. Epub 2011/03/09. S0166-4328(11)00162-8 [pii] https://doi.org/10.1016/j.bbr.2011.02.046 PMID: 21382419.

112. Ma W, Chabot JG, Quirion R. A role for adrenomedullin as a pain-related peptide in the rat. Proc Natl Acad Sci U S A. 2006; 103(43):16027–32. Epub 2006/10/18. 0602488103 [pii] https://doi.org/10.1073/pnas.0602488103 PMID: 17043245.

113. Fernandez AP, Serrano J, Martinez-Murillo R, Martinez A. Lack of adrenomedullin in the central nervous system results in apparently paradoxical alterations on pain sensitivity. Endocrinology. 2010; 151(10):4908–15. Epub 2010/09/23. 151/10/4908 [pii] https://doi.org/10.1210/en.2010-0121 PMID: 20858768.

114. Ishikawa T, Chen J, Wang J, Okada F, Sugiyama T, Kobayashi T, et al. Adrenomedullin antagonist suppresses in vivo growth of human pancreatic cancer cells in SCID mice by suppressing angiogenesis. Oncogene. 2003; 22(8):1238–42. Epub 2003/02/28. https://doi.org/10.1038/sj.onc.1206207 PMID: 12606950.

115. Conteduca V, Aieta M, Amadori D, De Giorgi U. Neuroendocrine differentiation in prostate cancer: current and emerging therapy strategies. Crit Rev Oncol Hematol. 2014; 92(1):11–24. Epub 2014/06/24. https://doi.org/10.1016/j.critrevonc.2014.05.008 PMID: 24952997.

116. D’Angiello RM, Greco C, Fiore M, Ippolito E, Eolo Trodella L, Iurato A, et al. Somatostatin analogs and disease control in castration-resistant prostate cancer: different biological behavior? Case series and review of the literature. Tumori. 2014; 100(3):249–53. Epub 2014/07/31. https://doi.org/10.1700/1578.17192 PMID: 25076233.

117. Thakur MK, Heilbrun L, Dobson K, Boemer J, Stark L, Li J, et al. Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer. Clin Genitourin Cancer. 2018; 16(3):e695–e703. Epub 2018/03/15. https://doi.org/10.1016/j.clgc.2018.01.019 PMID: 29534939; PubMed Central PMCID: PMCPMC6136146.